Shares of Nektar Therapeutics (NASDAQ:NKTR) added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to ...
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at William ...
Zacks Investment Research on MSN1d
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock UpNektar Therapeutics NKTR incurred an adjusted loss per share of 15 cents in the fourth quarter of 2024, wider than the Zacks ...
Full Year 2024 Results Key Financial Results Revenue: US$98.4m (up 9.2% from ...
Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target The firm is refreshing its model ahead of the company’s ...
2d
Despite a net loss, Nektar Therapeutics (NKTR) showcases promising developments in its autoimmune pipeline and maintains a ...
EDT Nektar (NKTR) up 12% to 91c after Oppenheimer upgrade with $6 targetLight Up your Portfolio with Spark:Easily identify stocks' risks ...
NEKTAR THERAPEUTICS ($NKTR) posted quarterly earnings results on Wednesday, March 12th. The company reported earnings of $0.15 per share, beating estimates of -$0.17 ...
Good day, and thank you for standing by. Welcome to the Nektar Therapeutics Fourth Quarter 2024 financial results conference call. At this time, all participants are in a listen-only mode.
SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Wednesday reported fourth-quarter earnings of $7.3 million. The San Francisco-based company said it had net income of 3 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback